Navigation Links
Omnicell Announces First Quarter 2011 Results
Date:5/2/2011

results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense related to ASC 718 is excluded from our non-GAAP financial measures:

i) While share-based compensation calculated in accordance with ASC 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation, under ASC 718, are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is ther
'/>"/>

SOURCE Omnicell, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Leading Hospitals Committed to Healthcares Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management
2. Omnicell is First to Demonstrate Automated Dispensing Cabinet Interoperability at HIMSS11 Showcase
3. Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference
4. Omnicell Announces Fourth Quarter and Full Year 2010 Results
5. Omnicell to Showcase Latest Product Innovations at ASHP
6. Omnicell Announces Third Quarter 2010 Results
7. Omnicell to Release Third Quarter 2010 Earnings Results on October 27
8. Omnicell Acquires Pandora Data Systems
9. Deaconess Health System Selects Omnicells Medication Management System for Product Reliability and Improved Patient Care
10. Wellmont Health System Selects Omnicell for Best-in-Class Medication Management
11. Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/21/2014)... 2014 McCord Research, Inc. was recently ... 8,796,315). This patent describes a method for accelerating ... the inventor, Dr. McCord, this method includes administering ... a composition of an effective amount of hydroxytyrosol ... blood, such that the administration of the combination ...
(Date:7/21/2014)... July 21, 2014  EHE International, the recognized leader ... nationwide physician network, today announced that Dignity Health Medical ... has been named an EHE-certified preventive care ... Las Vegas region now have greater access ... their health. "EHE is proud to ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2
... Acute Myeloid ... ... the U.S. Food & Drug Administration (FDA) has granted orphan,drug designation ... (AML)., Celator is currently preparing to conduct two randomized Phase ...
... in ,The Lancet, and Presented at ESC Congress-, ... new international,study, the GISSI Heart Failure (GISSI-HF) study, ... esters reduced all cause mortality and hospital,admissions for ... findings are published in this week,s online version ...
Cached Medicine Technology:Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... tests may one day help predict survival and the course ... also called Lou Gehrig,s disease, Italian researchers report. , , ... how fast ALS is progressing are called albumin and creatinine. ... health, according to the U.S. National Library of Medicine. ...
(Date:7/22/2014)... Boston University School of Medicine (BUSM) and Boston ... received care through BMC,s Violence Intervention Advocacy Program ... and social needs of violently injured youthswere less ... life changing behaviors through connections to caring, steady, ... hope. These findings are reported in the journal ...
(Date:7/22/2014)... The European Bio stimulants Market report defines and segments ... forecast of revenue. The bio stimulants market in Europe ... 2013 to $940.6 million by 2018, at a CAGR ... the TOC of the Europe Bio stimulants Market report, ... , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes to 10% ...
(Date:7/22/2014)... California (PRWEB) July 22, 2014 In ... women in recovery, the Marinello School of Beauty joined ... Addiction Treatment Center for a free “Make-over Day.” ... to be of service to the community, and The ... and renewed. They also gained some first-hand experience about ...
(Date:7/22/2014)... Ipswich, Mass. (PRWEB) July 22, 2014 ... of EBSCO Information Services , announces the ... to assist occupational health and safety professionals employed ... of chemicals and need to manage the impact ... , PoisonEXPERT provides access to relevant chemical-specific information ...
Breaking Medicine News(10 mins):Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 2Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3
... FALLS CHURCH, Va. and CUMMAQUID, Mass., April ... with research analysis partner Cambashi Ltd, today invited,medical ... on current industry,challenges and practices. The survey asks ... and applications, and,performance., The research team is ...
... function, researchers report , , WEDNESDAY, April 23 (HealthDay News) -- ... embryonic stem cells into three types of human heart muscle ... in mice. , The findings have a number of implications, ... cells to test drugs. , "We have now a supply ...
... 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY,), the global ... approval from the U.S. Food and Drug Administration (FDA) ... Deficit Hyperactivity Disorder (ADHD) in adults. VYVANSE, introduced ... children aged 6 to 12 years, is now the ...
... Florida,s elected leaders,received a message from thousands ... Governor Charlie Crist and legislative leaders not to,eliminate ... the state,s most,vulnerable citizens., Driven by ambulance ... gurney,the petitions ask Governor Crist, Senate President Ken ...
... announces the following Webcast:, What: Heska Corporation Invites You to ... Stockholders on the Web, When: Tuesday, May 6, @ 9:00 ... Stockholders link on the front ... Simply log on to the web at the ...
... Germany of a myocardial infarction is not higher for ... Deutsches rzteblatt International (Dtsch Arztebl Int 2008; 105(15): 279-85), ... disproved this widely held view. , ( http://www.aerzteblatt-international.de/v4/archiv/pdf.asp?id=59860 ... medical data from AOK (a large general statutory health ...
Cached Medicine News:Health News:Risk Management: Best Practices for Medical Device Profitability 2Health News:Embryonic Stem Cells Turned Into Three Types of Heart Cells 2Health News:FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults 2Health News:FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults 3Health News:FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults 4Health News:Thousands Sign Petitions Urging Governor Crist and Legislative Leaders to Save Healthcare Coverage for 40,000 Floridians 2Health News:Thousands Sign Petitions Urging Governor Crist and Legislative Leaders to Save Healthcare Coverage for 40,000 Floridians 3Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2
... Adams compact II centrifuge ... small laboratory. Attached, durable cover ... seals to minimize aerosol emissions, ... low temperature rise, brushless motor, ...
... Powerful ventilated floor-standing centrifuge. Mobile space ... large choice of accessories, analog controls, ... & shutdown (JOUAN patented pendulum system), ... and temperature limitation, rugged motor, tough ...
... utilize the infinity-corrected optical system ... in cell checking. The CKX31 ... suited to routine applications in ... culture and embryology to immunology ...
Continuous rocking motion graphic display....
Medicine Products: